Notice: This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GXGX vs. LRMR, ALDX, IMMP, BNTC, CMPS, FHTX, ACIU, NATR, AMLX, and LFCRShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Larimar Therapeutics (LRMR), Aldeyra Therapeutics (ALDX), Immutep (IMMP), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Foghorn Therapeutics (FHTX), AC Immune (ACIU), Nature's Sunshine Products (NATR), Amylyx Pharmaceuticals (AMLX), and Lifecore Biomedical (LFCR). These companies are all part of the "medical" sector. GX Acquisition vs. Larimar Therapeutics Aldeyra Therapeutics Immutep Benitec Biopharma COMPASS Pathways Foghorn Therapeutics AC Immune Nature's Sunshine Products Amylyx Pharmaceuticals Lifecore Biomedical Larimar Therapeutics (NASDAQ:LRMR) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk. Do insiders & institutionals have more ownership in LRMR or GXGX? 91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 61.7% of GX Acquisition shares are held by institutional investors. 3.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, LRMR or GXGX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.15-3.49GX AcquisitionN/AN/A-$49.26MN/AN/A Does the media refer more to LRMR or GXGX? In the previous week, Larimar Therapeutics had 22 more articles in the media than GX Acquisition. MarketBeat recorded 22 mentions for Larimar Therapeutics and 0 mentions for GX Acquisition. GX Acquisition's average media sentiment score of 0.00 beat Larimar Therapeutics' score of -0.18 indicating that GX Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Larimar Therapeutics Neutral GX Acquisition Neutral Which has more volatility & risk, LRMR or GXGX? Larimar Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Does the MarketBeat Community prefer LRMR or GXGX? Larimar Therapeutics received 38 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 68.97% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4068.97% Underperform Votes1831.03% GX AcquisitionOutperform Votes2100.00% Underperform VotesNo Votes Is LRMR or GXGX more profitable? Larimar Therapeutics' return on equity of -35.87% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% GX Acquisition N/A -985.20%-6.02% Do analysts prefer LRMR or GXGX? Larimar Therapeutics presently has a consensus target price of $20.43, indicating a potential upside of 409.44%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than GX Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09GX Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryLarimar Therapeutics beats GX Acquisition on 11 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.73M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book16.645.094.784.78Net Income-$49.26M$151.83M$120.31M$225.60M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$2.33+4.7%N/A+1,269.0%$83.73MN/A0.00N/AGap DownLRMRLarimar Therapeutics1.5648 of 5 stars$4.82-21.9%$20.43+323.8%-0.7%$307.56MN/A-3.5630Analyst RevisionNews CoverageHigh Trading VolumeALDXAldeyra Therapeutics2.4323 of 5 stars$5.07+3.5%$10.00+97.2%+45.7%$301.92MN/A0.0015Positive NewsIMMPImmutep1.4097 of 5 stars$2.07-5.0%$8.50+310.6%-11.4%$301.10M$5.14M0.002,021BNTCBenitec Biopharma3.5941 of 5 stars$12.76+8.4%$24.43+91.4%+264.5%$296.29M$80,000.000.0020Analyst RevisionCMPSCOMPASS Pathways2.8201 of 5 stars$4.29+1.7%$33.60+683.2%-50.5%$293.53MN/A-1.92120Positive NewsFHTXFoghorn Therapeutics2.8803 of 5 stars$5.27-0.6%$16.00+203.6%-18.2%$292.98M$25.52M-2.63120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeACIUAC Immune2.4666 of 5 stars$2.95flat$12.00+306.8%-36.5%$291.87M$16.48M-6.41140Positive NewsNATRNature's Sunshine Products3.7933 of 5 stars$15.69+0.5%$19.00+21.1%-16.6%$289.89M$445.10M17.55814Positive NewsAMLXAmylyx Pharmaceuticals4.2625 of 5 stars$4.18+1.5%$7.33+75.4%-71.0%$286.53M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsLFCRLifecore Biomedical2.9047 of 5 stars$7.71+1.3%$10.00+29.7%+19.7%$283.94M$128.44M97.50690 Related Companies and Tools Related Companies LRMR Competitors ALDX Competitors IMMP Competitors BNTC Competitors CMPS Competitors FHTX Competitors ACIU Competitors NATR Competitors AMLX Competitors LFCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GXGX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
